Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
University of Pittsburgh Medical Center to spend big on drug development
by Megha Satyanarayana
January 16, 2020
| A version of this story appeared in
Volume 98, Issue 3
UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center, says it will spend $1 billion over the next 4 years to develop new drugs, diagnostics, and medical devices. The investment includes a previously announced $200 million to support an immunotherapy venture with the University of Pittsburgh. In the past 2 years, UPMC Enterprises has launched five companies and invested in another, Werewolf Therapeutics. In addition to immunotherapy, it will target respiratory disease and neuroinflammation, among other illnesses.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter